Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#96 / 96 Total
DNLI - Denali Therapeutics Inc - Stock Price Chart
CompanyDenali Therapeutics Inc
Market Cap3.21BEPS (ttm)-0.97
P/E-EPS this Y-165.80%
Forward P/E-EPS next Y3.96%
PEG-EPS past 5Y-21.99%
P/S10.86EPS next 5Y-
P/B2.20EPS Q/Q15.26%
Dividend-Sales Q/Q-100.00%
Insider Own17.83%Inst Own82.00%
Insider Trans-0.76%Inst Trans-0.74%
Short Float7.96%EarningsMay 07/a
Analyst Recom1.13Target Price39.43
Avg Volume1.10M52W Range14.56 - 31.44
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cook Jennifer E.DirectorJun 06 '24Sale21.731,45831,68220,038Jun 10 08:06 PM
SATO VICKI LDirectorMay 15 '24Sale20.391,67434,133116,369May 17 04:28 PM
SATO VICKI LDirectorApr 15 '24Sale18.291,66630,471118,043Apr 17 05:14 PM
Krognes Steve E.DirectorApr 01 '24Sale20.5092,5001,896,25047,341Apr 02 06:07 PM
SATO VICKI LDirectorMar 15 '24Sale20.101,66633,487119,709Mar 19 04:27 PM